When: Price retests $377-365 zone with RSI holding >40

Then: Scale-in per sizing rules

When: Confirmed weekly close >$420 on volume with 200 SMA slope flattening

Then: Upgrade to Overweight

When: Break below $365 on rising volume

Then: Downgrade to Underweight

HOLD

• Q2 revenue acceleration of 18.5% and 23% net income growth already priced in after 20% rally from July 23rd low
• US procedure growth decelerated despite management framing it as ACA-driven deferral; domestic engine (highest-margin segment) showing cracks
• 200-SMA at 479 rolling over; price 16% below it; ATR elevated at 13.36; 3% average daily range
• July 17th regime event: 14% single-session drop on 11.5 million shares followed by V-shaped recovery
• Oppenheimer $500 target is one desk's view, not institutional consensus; requires multiple expansion, earnings delivery, and constructive macro
• J&J Ottava FDA approval creates direct competition from largest healthcare company in the world; multiple compression risk before revenue loss
• Proposed 332 stop is inadequate: 12% drawdown on stock with 20-40% realized volatility profile and beta of 1.46
• Scaling aggressively at 401-406 means buying at upper Bollinger Band into resistance vs waiting for 377-365 support zone
• Position ceiling of 5% of portfolio with 15% loss on stop vs 20% gain if stock reaches 480 represents asymmetric risk framework
• 2024 buyback pause and 2025 resumption reflects management capital allocation responsiveness, not directional business signal

→ vs aggressive: Q2 beat is in the rearview mirror; market already priced the 20% rally from July low; domestic procedure growth deceleration contradicts operational inflection narrative

→ vs aggressive: 200-SMA signal invalidation is not valid: it reflects 200 days of price action; price 16% below it rolling over is medium-term reality, not lagging artifact

→ vs aggressive: One Oppenheimer upgrade does not constitute institutional consensus; $500 target requires multiple expansion into hostile macro (86% zero Fed cuts probability in 2026)

→ vs aggressive: J&J Ottava approval is not a non-event; competitive moat erodes gradually with multiple compression before revenue loss materializes

→ vs aggressive: 332 stop (12%) is inadequate for 20-40% drawdown profile; ATR is 13.36 on 400 stock = 3% daily range; not a stop, a coin flip

→ vs aggressive: Scaling at 401-406 is paying 5-8% more per share at upper Bollinger Band with no fundamental change; trader's existing plan specifies 377-365 for better risk-adjusted entry

→ vs aggressive: HOLD is not performance anxiety; asymmetric loss framework means no single position should damage portfolio beyond risk framework tolerance

HOLD

• Q2 operational inflection is real: 18.5% revenue growth (up from 13.6% in Q1) with gross margin at 67.8% and operating margin at 33.6% establishes a higher earnings baseline
• 200 SMA at 4.79 rolling over signals medium-to-long-term structural headwinds; short-term bullish momentum within broken longer-term structure is textbook counter-trend rally definition
• Forward multiple of 33x on $12.07 EPS is fairly valued at best, priced for perfection at worst given 1.46 beta
• Oppenheimer upgrade is one credible desk but does not represent consensus; da Vinci 5 adoption and Ottava competition remain unknowns
• Position sizing at 5% or less with hard stop below 3.32 (July capitulation low) is appropriate discipline for a 42% peak-to-trough drawdown history
• Scaling in zone: 3.77 to 3.65, conditional on RSI holding above 40 on retest to avoid buying into dead cat bounce
• Trim zone: 4.06 to 4.20, with specific failure condition—fail to close above 4.06 on volume within two weeks triggers at least one-third position reduction
• Trailing stop component: if stock closes above 50 SMA (3.92) for 3 consecutive sessions, tighten stop to breakeven or slightly below entry at 3.77
• ATR of 13.36 means average daily range exceeds 3%, making position sizing and stops critical risk management tools
• Key catalysts to force directional upgrade/downgrade: September Fed meeting, next quarter US procedure growth print, Ottava commercial launch data

→ vs aggressive: Adding at 4.01 to 4.06 near upper Bollinger Band with ATR over 3% is not aggressive—it's impatient; scaling should target lower band not upper band per mean reversion logic

→ vs conservative: The 12% stop at 3.32 is not a coin flip—it is a defined risk parameter below the July 23 capitulation low, sizing the position at 5% or less addresses high volatility rather than abandoning disciplined stops

→ vs conservative: Q2 print is not fully priced in; the stock bottomed July 23, earnings released early August, and the bounce to 4.01 happened during/after—the new revenue growth trajectory and margin expansion are higher than consensus modeled three months ago